Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Trial of NSI 566 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

A Phase III Trial of NSI 566 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NSI 566 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Palisade Bio; Seneca Biopharma
  • Most Recent Events

    • 09 Apr 2020 According to a Seneca Biopharma media release, the company received significant guidance from FDA regarding an acceptable trial design and is in the process of developing the protocol for further review.The company looks forward to working closely with the Agency on finalizing the design of this Phase 3 trial for the devastating disease.
    • 09 Apr 2020 According to a Seneca Biopharma media release, as a result of the discussion and feedback received from the FDA, Seneca believes that the existing phase 1 and 2 trial results support moving into this phase 3 clinical study for ALS.
    • 09 Apr 2020 According to a Seneca Biopharma media release, the company held a Type C meeting with the Office of Tissues and Advanced Therapies at the FDA on 10th Mar 2020 to discuss future clinical development plans for NSI-566, for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top